« Return to News | Drug Sponsors

Roche extends Illumina tender offer

Monday, February 27, 2012 03:17 PM

Roche has extended its cash tender offer to acquire all outstanding shares of Illumina at $44.50 per share to 6 p.m., Eastern Standard Time, on March 23, 2012.

The tender offer was previously scheduled to expire at midnight on Feb. 24. At that time, approximately 102,165 shares had been tendered and not withdrawn pursuant to the offer. The terms and conditions of the extended offer remain unchanged.

In response, Illumina said, “The extension by Roche was expected. An extremely low number of shares have been tendered, consistent with our view—and that of our stockholders—that Roche’s offer does not reflect Illumina’s unique leadership position, business performance and future prospects.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.